cerulean


Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • all
  • noun
  • adj

Synonyms for cerulean

a light shade of blue

of a deep somewhat purplish blue color similar to that of a clear October sky

References in periodicals archive ?
disclosed Sunday that it had offered $675 million for Cerulean, topping the previous $500 million cash and stock offer from WellPoint.
Cerulean Rose could have the Ayr Gold Cup, or Silver Cup, on the agenda if she wins today.
WellPoint expects the Cerulean merger to close in December.
In Sho, 1997, traces of cerulean blue underpainting show through thickly applied layers of olive and a dull verdigris green, giving the composition a surprising depth.
Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs.
If the DarA(c) Transaction is consummated, then under the terms of the agreement, Cerulean stockholders will hold between 30% and 49% of the combined company at closing, depending on the amount of cash each of Cerulean and DarA(c) have at closing.
M2 EQUITYBITES-March 21, 2017-DarA(c) Bioscience to Become Majority Owner of US Drugmaker Cerulean Pharma
Cancer treatment company Cerulean Pharma (Nasdaq:CERU) said on Friday that it has completed its public offering of 6,716,000 shares of common stock at a public offering price of USD6.
The ten-year-old could finish no closer than eighth behind the well-backed Cerulean Rose after struggling to go the pace throughout.
22 earnings estimate and the anticipated closing of WellPoint's merger with Cerulean Companies Inc.
and we are truly honored that Cerulean is the only biotechnology company represented on the list," said Oliver Fetzer, Ph.
V Cerulean containers, Project Terminal, Engro Vopak Terminal and Multi Purpose Terminal respectively on Tuesday.
Cerulean Pharma Inc (Nasdaq: CERU), a US-based pharmaceutical company involved in Dynamic Tumor Targeting, has announced that it has signed a clinical research agreement with the GOG Foundation Inc.
Despite delays in completing its acquisition of Cerulean Companies Inc.